XXXXXXXX XXXXXX X XXXXXXXXX XXXXXXXXX (XX) x. 1062/2014
xx xxx 4. xxxxx 2014,
xxxxxxxx xx xxxxxxxxxx programu systematického xxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxx látek xxxxxxxxxx x xxxxxxxxxx přípravcích, xxxxx xxxx xxxxxxx x xxxxxxxx Evropského xxxxxxxxxx x Xxxx (XX) x. 528/2012
(Text x xxxxxxxx pro XXX)
XXXXXXXX XXXXXX,
x xxxxxxx xx Xxxxxxx x xxxxxxxxx Xxxxxxxx xxxx,
x ohledem na xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx (EU) x. 528/2012 xx xxx 22. xxxxxx 2012 x xxxxxxxx xxxxxxxxxx přípravků xx xxx a xxxxxx xxxxxxxxx (1), a zejména xx xx. 89 xxxx. 1 xxxxx xxxxxxxxxxx uvedeného nařízení,
vzhledem x xxxxx xxxxxxx:
|
(1) |
Xxxxxxxx Xxxxxx (XX) x. 1451/2007 (2) xxxxxxx xxxxxxxxx pravidla xxx program xxxxxxxx xxxxxxxxxxx biocidních xxxxxxxx xxxxx (dále xxx „xxxxxxx přezkumu“), xxxxx xxx xxxxxxx x xxxxxxx x xx. 16 xxxx. 2 xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx 98/8/XX (3). Xxxxxxx tato xxxxxxxx byla xxxxxxx x xxxxxxxxx xxxxxxxxx (XX) x. 528/2012, xxxx xx xxx prováděcí xxxxxxxx xxx pokračování programu xxxxxxxx přizpůsobena ustanovením xxxxxxxxx nařízení. |
|
(2) |
Xx xxxxxxxx xxxxx kombinace xxxxxx xxxxx a xxxx xxxxxxxxx, které xxxxx xxx xxxxxxxx xx xxx x xxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxxxx xxxxxx 89 nařízení (XX) x. 528/2012 x xxxxxxxx xxxxxxxxxxxxxx předpisů. Mělo xx xxxx xxx x v případě xxxxxxxxx účinné xxxxx x xxxx xxxxxxxxx, xxxxx xxxx xxxxxxxxx x xxxxxxxx xxxxxxxx. |
|
(3) |
Pokud xxxxxxxxx xxxxxxxx odchylky xxx xxxxxxxxx x xxxxxx xxxxx xxxxxx 6 xxxxxxxx (XX) x. 1451/2007, xxx xxxxxxxxxx xx xx xxx xxxxxxx xxx potraviny x xxxxxx xxxxxxx x xx. 2 odst. 5 xxxx. x) xxxxxxxx (XX) x. 528/2012, měly xx xxx účinné látky, xxxxx xxxxxxxx, xxxxxxxxx x xxxxxxxx přezkumu xxx xxxxxxxxx xxx přípravku. X xxxxxxxx vnitrostátních xxxxxxxx xx mělo být xxxxxx dodávání na trh x xxxxxxxxx xxxxxxxx xx xx xxxxxxxx xxxxxxxxx xxxxxxxxx. Xxxxxx xxxxxxxxxxx prohlášení xx xxx vymezit, xxxxx přípravky tohoto xxxxxxxxxx xxxxxxx. Xxxxx xx xxxx xxxxxx x xxxxxxxxx, xxx xxxxxxxxxx xxxxxxxxx účinné látky x xxxx xxxxxxxxx xxxxxxxxx x xxxx xxxxxxxx xxxx přípravků x xxxxxxxx (XX) x. 528/2012 oproti xxxxxxxx uvedené ve xxxxxxxx 98/8/XX nebo xx xxxxx xxxxxxxxxx xxxxxxxxxxx Komise xxxxxxxx x xxxxxxx s čl. 3 xxxx. 3 xxxxxxxx (XX) x. 528/2012, xxxxxxxxxxx (například xxxxxxxxxxx xx xxxx C-420/10 (4)) xxxx závaznými pokyny Xxxxxx xx xxxxxxxxxxx xxxxxx xxxxxxxxx států, xxxxx xx xxxxxxxx xxxxxxx. |
|
(4) |
Xxxxx biocidní přípravek xxxxxxxx xxxxxxx xxxxx, xxxxx již není xxxxxxxx xx programu xxxxxxxx, z této xxxxx xxxxxxx xxxx xx x xx xxxxxx, avšak xxxxxxxx xx xxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxx x xxxxxxxx xxxxx xxxxxxxx, mělo xx xxx x xxxxx xxxxxxxx xxxxx xxxxxxx x dodávání xx xxx xxxxxxxx xx xxxx xxxxxxxxxxxx, za xxxxxxxx xxxxxxxx x xx omezenou xxxx. |
|
(5) |
X xxxxx xxxxxxxxxxx x xxxxxxxxxxxx xx xxx xxx xxxxxx xxxxxxxxx xxxxxxxx xxxxx v programu xxxxxxxx xx všech xxxxxxxxxx částech totožný x xxxxxxxx xxxxxxxxxx xxx xxxxxxx xxxxxxxxxx xxxxx xxxxxx 7 xxxxxxxx (XX) x. 528/2012 xxxx xxxxx xxxxxxxxxxx nařízení Xxxxxx (XX) x. 88/2014 (5). |
|
(6) |
Xxx xxxxx, xxxxx xxxxxxx xxxxxxxx xxxxxxxxx nebo xxxxxxxx xxx náhradu, xx xxx xxxxxxxxx xxxxxxxxx xxxxx předložit xxxxxxxx xxxxx harmonizované xxxxxxxxxxx x xxxxxxxx xxxxx xxxxx xx. 37 xxxx. 1 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (ES) x. 1272/2008 (6), xxxxx jde x xxxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxx, a zároveň xx xxxx xxx xxxxxxxxx xxxxx xxxxxxxxx státu xxxxxxxxx návrh xxxxxxxx xx xxxxxx xxxx xxxxx sledovaných vlastností. Xxxxxxxxx xxxxxxxxx xxxxx xx xxx xxxx xxxxxxxxxxx agenturu v xxxxxxx xxxxx, které xx xxxxxxxxx kritéria xxx xxxxx xxxxxxxxxxxx, xxxxxxxxxxxxxxx xx xxxxxxx, xxxx xxxxx, xxxxx xx xxxxx být xxxxxxxxxx xx xxxxx x xxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx. |
|
(7) |
Xxx bylo xxxxxxxxx, xx program přezkumu xxxx xxxxxxxx xx xxxxxxxx data uvedeného x xx. 89 odst. 1 xxxxxxxx (XX) x. 528/2012, mělo xx xx xxxxxxxxx xxxxxx na xxxxxxxxx xxxxxx látky x xxxx xxxxxxxxx, u xxxxx xxxx xxxxxxxxx xxxxx xxxxxxxxxx ve lhůtách stanovených x xxxxxxxx (XX) x. 1451/2007 xxxx x xxxxx nařízení. Xxxxx xxxx xx xx xxxx xxxxxxxx xxxxxx lhůty pro xxxxxxxxx xxxxxxxxx, xxxxxxx xx xx xxxx xxxx v xxxxx xxxxxxx, xx xxxxxxx xx xxxxx xxx xxxxxxxxx xxxx než xxx xxxx uplynutím xxxxxx xxxx. |
|
(8) |
Xxxxxxx xxxxxxxx xx přílohy I xxxxxxxxx 7 xxxxxxxx (XX) x. 528/2012 dosud xxxxxx xxxxxxxxx xxxxx xxxxxxxxx xx xxxxx. Xx xxxxx xxxxxx x xxxx fázi xxxxxx xxxxxxx o zařazení xx xxxxxxx přílohy xx kategorie 1, 2, 3, 4, 5 nebo 6. |
|
(9) |
Bez xxxxxx na čl. 90 xxxx. 2 xxxxxxxx (XX) x. 528/2012 xxxxxxx x xxxxxx 91 xxxxxxxxx xxxxxxxx, xx xxxxxxxx uvedená x xxxxxx 10 xxxxxxxxx xxxxxxxx xx xxxx být relevantní xxx xxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx xx xxxxx xxxxxxxxx. Xx xxxxx xxxxxx určit xxxxx xxxxxxxxx tato xxxxxxxx xx xxxxx xxxxxxxxxxx účinných xxxxx. |
|
(10) |
Xxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx xx xxx xxx možnost xx xx xxxxxxxx xxxxxx xxxxxxxx ke stávajícímu xxxxxxxxxxx xxxx xxx xxxxxxxx xx předpokladu, xx xxxxx tomu xxxxxxx ke zpoždění xxxxxxxxx z důvodu xxxxxxxxx xxxxxxxx x údajům, xxxxxxx xxxxx by xxxxxxxxxxx xxxxxxxx musel xxxxxxxxx údaje znovu. |
|
(11) |
Protože xx účast x xxxxxxxx xxxxxxxx xxxxxxxxxx, xxxx xx být účastníkům xxxxxxxx xx ní xxxxxxxxx. Xxxxx k xxxx xxxxx, xxxx xx xxx xxxxxxxxxxx xxxxxxxxx možnost převzít xxxxxxx, nebylo-li této xxxxxxxx xxxxxxx xxx xxxxxx, xxxxx xxx xxxxxxx xx xxxxxxxx xxxxxxxx xxxxxxxx, x xxxxxxxx-xx agentura xxx xxxxxxxx xx xxxx xxxxxxxxxx. |
|
(12) |
Xxxxx xx při xxxxxxxxx účinné látky xxxxx, že identita xxxxxxxxx xxxxxxxx do programu přezkumu xxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxx, x x xxxxxxxxx xxxxx xxxxxxx závěry ohledně xxxxxxxx xxxxxxxxx xxxxxxxx xxxxx, mělo xx xxx možné xxxx xxxxx x xxxxxxx xxxxxxxxx xxxxx xxxxxxxxx a povolit xxxxx osobám, xxx xxxxxxxx xxxxxxx této xxxxxxxxx xxxxxxxx látky. |
|
(13) |
Některé xxxxx xxxxxxxx do xxxxxxxx přezkumu nejsou x xxxx přijetí xxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx účastníkem. Totéž xx týká určitých xxxxxxxxxxxxx, xxxxxx podle xx. 4 xxxx. 4 xxxxxxxx (XX) č. 528/2012 tyto xxxxxxxxx nelze xxxxxxxx, xxxxx tak xxxx xxxxxxxx stanoveno. X xxxxxxxxx látek a xxxxxxxxxxxxx xx xxxx xxx xxxxx možnost xxxxxxx účast, protože xxxxx xx xxxx xxxxx x xxxxxxxxxxxxx xxxxxx xxx x programu xxxxxxxx xxxxxxxxx. |
|
(14) |
Xxx bylo xxxxxxxxx, že žádná xxxxx xxxxxxxxx v xxxxxxxx neoprávněně xxx xx xxx xxxxxx xxxxxxxx, aniž xx xxxxxxxx xxxx xxxxxxxxxxx, xxxx xx xxxxxxxx xxxxx, xxxxx xxxxx xxxxxx hodnocena, x xxxxxxxx nebo xxxx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxx údajů o xx, |
XXXXXXX XXXX NAŘÍZENÍ:
KAPITOLA 1
XXXXXXX X XXXXXXXX
Xxxxxx 1
Xxxxxxx
Xxxx xxxxxxxx xxxxxxx pravidla pro xxxxxxxxx pracovního xxxxxxxx xxxxxxxxxxxxxx přezkumu všech xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx x&xxxx;xxxxxx&xxxx;89 xxxxxxxx (XX) č. 528/2012.
Xxxxxx 2
Xxxxxxxx
Xxx xxxxx xxxxxx xxxxxxxx se xxxxxxx xxxx xxxxxxxx:
|
x) |
„xxxxxxxxxxx x neschválení“ xx xxxxxx xxxxxxxxxx neschválit xxxxxxxxx látky x xxxx xxxxxxxxx xxxxx xx. 9 xxxx. 1 xxxx. x) xxxxxxxx (XX) x. 528/2012 nebo xx. 89 xxxx. 1 třetího xxxxxxxxxxx xxxxxxxxx xxxxxxxx, xxxx xxxxxxxxx nezařadit xx xxxxxxx X xxxx IA xxxxxxxx 98/8/XX; |
|
x) |
„xxxxxxxxx xxxxx x xxxx xxxxxxxxx zařazenou xx xxxxxxxx xxxxxxxx“ xx xxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxx x xxxxxxx XX, která xxxxxxx xxxx xxxxxxxx:
|
|
x) |
„xxxxxxxxxx“ se xxxxxx osoba, xxxxx xxxxxxxxxx xxxxxx o xxxxxxxxx látky x xxxx xxxxxxxxx xxxxxxxx xx xxxxxxxx xxxxxxxx xxxx xxxxxxxxxx xxxxxxxx, xxxxx xxxxxxxx xxxxxxxxxx xxxxx xx. 17 xxxx. 5 xxxxxx xxxxxxxx, xxxx jejímž xxxxxx xxxx xxxx xxxxxx xxxx xxxxxxxx xxxxxxxxxx; |
|
x) |
„xxxxxxxxxx xxxxxxxxxx xxxxxxx“ xx xxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxx xxxxxxxxx x xxxxxxx XX xxxxxx xxxxxxxx, xxxxxx x xxxxxxx x xxxxxxx 81 nařízení (XX) x. 528/2012. |
KAPITOLA 2
POSTUP XXXXXXXXX XXXXXXXXXXX
Xxxxxx 3
Xxxxxx x xxxxxxxxx nebo xxxxxxxx xx xxxxxxx I xxxxxxxx (XX) x. 528/2012
1.&xxxx;&xxxx;&xxxx;Xxxxxx o schválení xx xxxxxxxx xx&xxxx;xxxxxxx X&xxxx;xxxxxxxx (XX) č. 528/2012 xxxx xxxxx xxxxx účastník, x xxxxx oznámení xxxxx xxxxxxxx k xxxxxx, xx xxxxxxxx xxxxxxxxxx xxxxx xx.&xxxx;17 xxxx.&xxxx;5 xxxxxx xxxxxxxx.
Xxxxx xx xxxxxx xxxx xxxxxxxx xx&xxxx;xxxxxxx X&xxxx;xxxxxxxx (XX) č. 528/2012, xxxx xx týkat xxxxx xxxxxxxxx 1, 2, 3, 4, 5 xxxx 6 uvedené xxxxxxx.
2.&xxxx;&xxxx;&xxxx;Xxxxxxx uvedené x&xxxx;xxxxxxxx 1 se xxxxxxxx xxxxxxxx xx&xxxx;xxxx let xx xxxxxxxxxx x&xxxx;xxxxxxx x xxxxxxxxx xxxxx xx.&xxxx;17 xxxx.&xxxx;5.
Xxxxxx 4
Xxxxxxx xxxxxxx
1. Xxxxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx xxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxx Xxxxxx (XX) č. 564/2013 (7) x zamítne xxxxxx, xxxxx xxxxxxxx nezaplatí xxxxxxxx xx lhůtě 30 xxx. X xxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxxx x hodnotící xxxxxxxxx xxxxx.
2. Po obdržení xxxxxxxx xxxxxxxxx podle xxxxxxxxxxx xxxxxxxx (EU) x. 564/2013 xxxxxx xxxxxxxx xxxxxx a informuje x tom xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxx, xxxxxxx uvede datum xxxxxxx xxxxxxx x xxxx xxxxxxxxx identifikační xxx.
3. Xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxx 1 tohoto xxxxxx xxx podat xxxxxxx prostředek x xxxxxxx x xxxxxxx 77 xxxxxxxx (EU) x. 528/2012.
4. Hodnotící xxxxxxxxx xxxxx informuje účastníka x xxxxxxxx xxxxxxxx xxxxx xx. 80 xxxx. 2 xxxxxxxx (XX) č. 528/2012 xx 30 xxx xxxx, co xxxxxxxx xxxxxxx xxxxxx, x xxxxxxx xxxxxx, xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xx xxxxx 30 xxx. O této xxxxxxxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx.
Xxxxxx 5
Xxxxxxxxx xxxxxxx x xxxxxxxxx xxxx xxxxxxxx xx xxxxxxxxx 6 xxxxxxx X xxxxxxxx (EU) x. 528/2012
1. Xxxxx agentura xxxxxx xxxxx xx. 4 xxxx. 2 xxxxxx x xxxxxxxxx xxxx zařazení xx xxxxxxxxx 6 xxxxxxx X xxxxxxxx (XX) č. 528/2012, xxxxx xxxxxxxx údaje xxxxxxxxxx x xxxxxxx x xx. 6 xxxx. 1 x 2 xxxxxxxxx nařízení, x xxx xxxxxxxx xxxxxxxx xxxxx xx. 4 xxxx. 4, hodnotící xxxxxxxxx xxxxx xxxxxx xxxxxxx xx 30 dnů xx xxxxxxxxx poplatků.
2. Xxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxx xx xxxxxxxxx dokumentaci xxxxx xxxxxxxx (XX) x. 1451/2007, xxxxx ta xxxxx nebyla uznána xxxx xxxxx xxxxx xxxxxx 13 uvedeného xxxxxxxx, potvrdí xxxxxxxxx xxxxxxxxx xxxxx xxxxxx xxxxxxxxxx xx 3. xxxxx 2015.
3. X xxxxxxxxx xxxxxxxxx x odstavcích 1 x 2 hodnotící xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxx kvality xxx xxxxxxxxxxxx xxxxxxxxxxxx xxxxx xxxx odůvodnění.
4. Xxxxx hodnotící xxxxxxxxx xxxxx xxxxxx, xx žádost xx xxxxxxx, sdělí účastníkovi, xxxx doplňující xxxxxxxxx xxxx x potvrzení xxxxxxx xxxxx, x x xxxxxxxxxx těchto xxxxxxxxx xxxxxxx xxxxxxxxxx xxxxx. Tato lhůta xxxxx nepřesáhne 90 dnů.
Xxxxxxxx-xx xxxxxxxxx xxxxxxxxx xxxxx, xx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxx ke xxxxxxx požadavků xxxxxxxxx x xxxxxxxx 2, xxxxxxx xxxxxx xx 30 xxx xx xxxxxxxx doplňujících xxxxxxxxx.
Xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxx xx xxxxxxxxx xxxxx xxxxxxxxxx, xxxxxxxxx xxxxxxxxx xxxxx xxxxxx zamítne x xxxxxxxxx x xxxx xxxxxxxxxxx účastníka x agenturu. X xxxxxx xxxxxxxxx xx xxxxx xxxxxxxx xxxxxxxxx x xxxxxxx x xx. 80 odst. 1 x 2 xxxxxxxx (EU) x. 528/2012.
Xxx potvrzení xxxxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxxxxxx x xxxxx xxxxxxxxx xxxxxx x xxxxx datum xxxxxx potvrzení.
Xxxxxx 6
Xxxxxxxxx xxxxxxx
1. Xxxxx xxxxxx xx použije, xxxxx xxxxx xxxxxxx x xxxxxx xxxxxxxx:
|
x) |
xx-xx žádost xxxxxxxxx podle xxxxxx 5; |
|
x) |
xxxxx hodnotící xxxxxxxxx xxxxx xxxxx dokumentaci xxxx xxxxxx xxxxx xxxxxx 13 xxxxxxxx (ES) x. 1451/2007, xxx dosud xxxxxxxxxxx Komisi zprávu xxxxxxxxxxx xxxxxx podle xx. 14 xxxx. 4 uvedeného xxxxxxxx; |
|
x) |
xxxxx agentura xxxxxxx xxxxxx x xxxxxxxx xx xxxxxxxxx 1, 2, 3, 4 xxxx 5 xxxxxxx X xxxxxxxx (XX) č. 528/2012 xxxxx xx. 4 odst. 2 x xxx zaplacen poplatek xxxxx xx. 4 xxxx. 4. |
2. Hodnotící xxxxxxxxx xxxxx zhodnotí xxxxxx xxxxx xxxxxx 4 x 5 xxxxxxxx (EU) č. 528/2012 x případně xxx xxxxxxx xxxxxx xx xxxxxx požadavků xx xxxxx předložené x xxxxxxx s xx. 6 xxxx. 3 xxxxxxxxx xxxxxxxx x xxxxx hodnotící xxxxxx a závěry xxxxx xxxxxxxxx agentuře.
3. Xxxxx xxxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxxxx xxxxxxx účastníků, xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx pouze xxxxx xxxxxxxxx zprávu. Xxxxxxxxx xxxxxx x xxxxxx xxxxx x xxxxx x xxxxxx xxxx, podle xxxx, xx nastane později:
|
x) |
365 xxx po xxxxxxxxx xxxxxxxxx xxxxxxxx x xxxx. 1 xxxx. x), xxxxxx xxxxxxxx xxxxxxxx x xxxx. 1 xxxx. x) xxxx xxxxxxxxx poplatku xxxxxxxxx x xxxx. 1 písm. c) x xxxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx; |
|
b) |
xx xxxxx xxxxxxxxx v příloze XXX. |
4. Xxxx tím, xxx xxxxxxxxx příslušný xxxxx xxxxxxxx své xxxxxx xxxxxxxx, umožní účastníkovi xxxxx xx 30 xxx k xxxxxxxxx xxxxxx x k xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxx. Xxxxxxxxx xxxxxxxxx xxxxx xxxx připomínky xxxxxxxxxxxxx způsobem xxxxxxxx x xxxxxxxxx xxxx xxxxx xxxxxxxxx.
5. Xxxxx se xxxxx, xx xxxx x hodnocení xxxxx xxxxxxxxxx xxxxxxxxx, xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxx, xxx xxxx xxxxxxxxx xx stanovené xxxxx xxxxxxxxx, a xxxxxxxxx x tom xxxxxxxx.
Xxxxx 365 xxx xxxxxxx x xxxxxxxx 3 xx xxxxxxx xx xxxx xxx xxx xxxxxxxx požadavku xx dne xxxxxxxx xxxxxxxxx. Pokud xx xxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxx xxxxx xxxx xxxxxxxxxxx xxxxxxxxxx, xxxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxx:
|
a) |
365 xxx x xxxxxxx, xx xx doplňující xxxxxxxxx xxxxxx xxxxxx, xxxxx xxxxxx xxxxxx x xxxxx směrnice 98/8/XX xxxx v rámci xxxxxxx xxxxxxxxxxx pro xxxxxxxxxxx xxxxxxx směrnice; |
|
x) |
180 xxx xx xxxxx xxxxxxxxx případech. |
6. Xxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxx, že existují xxxxx xxxxxxx xxxxxx xxxx xxxx xxxxxx xxxx xxxxxxxxx prostředí xxxxxxxxxxx x xxxxxxxxxxxxx xxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxxxx přípravků xxxxxxxxxxxx stejné xxxx xxxxxxxx xxxxxx xxxxx, xxx obavy zdokumentuje x xxxxxxx x xxxxxxxxx xxxxxxxxxxx xxxxx xxxxxx XX xxxx 3 xxxxxxx XX nařízení Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 1907/2006 (8) x xxxxxx xx do xxxxx xxxxxx.
7. X xxxxxxx xxxxxxx xx dokončení xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx xxx zbytečného xxxxxxx x xxxxxxxxxx xxx xxxxxxxxxx hodnotící xxxxxx xxxxx xxxxxxxx 3:
|
x) |
xxxxxxxx xxxxx xxxxxxxx podle xx. 37 xxxx. 1 xxxxxxxx (XX) x. 1272/2008, jestliže xx xxxxxxx, xx xx xxxxxxx jedno z kritérií xxxxxxxxx x xx. 36 xxxx. 1 xxxxxxxxx nařízení, xxx xxxx xxxxxxxx řešeno x xxxxx 3 xxxxxxx XX xxxxxxxxx xxxxxxxx; |
|
x) |
xxxxxxxxxx s agenturou, xxxxx xx xxxxxxx, xx xxxxx z kritérií xx. 5 xxxx. 1 xxxx. x) xxxx x) xxxxxxxx (EU) x. 528/2012 nebo podmínka xx. 10 odst. 1 xxxx. x) xxxxxxxxx nařízení jsou xxxxxxx, ale xxxxxx xxxxxxxx xxxxxx x xxxxxxx XXX xxxxxxxx (ES) x. 1907/2006 nebo v seznamu xxxxxxxx x xx. 59 xxxx. 1 xxxxxxxxx xxxxxxxx. |
Xxxxxx 7
Xxxxxxxxxx agentury
1. Tento xxxxxx xx xxxxxxx, xxxxx xxxxx xxxxxxx x xxxxxx xxxxxxxx:
|
x) |
xxxxx xxxxxxxxx xxxxxxxxx orgán předložil xxxxxxxxx xxxxxx podle xx. 6 xxxx. 2 x xxxxxxxx xxxxxxxxx xxxxx xxxx xxxxxxx konzultaci xxxxx xx. 6 xxxx. 7; |
|
x) |
pokud xxxx předložena Xxxxxx xxxxxx xxxxxxxxxxx xxxxxx xxxxx čl. 14 odst. 4 xxxxxxxx (ES) x. 1451/2007, xxx xxxxxxxxx zprávu xxxxx xxxxxxxxxxxx Stálý xxxxx xxx xxxxxxxx xxxxxxxxx xxxxx xx. 15 xxxx. 4 uvedeného nařízení. |
2. Xx xxxxxxx xxxxxx xxxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxx x xxxx přípravku xxxx xxxx xxxxxxxx xx xxxxxxxxx 1, 2, 3, 4, 5 xxxx 6 xxxxxxx X xxxxxxxx (XX) č. 528/2012, xxxxxxxx xxxxxx, x xxxxxxx xx xxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxx.
Xxxxxxxx xxxxxx xxxxxxxx xxxxxxxxxx x xxxxx x xxxxxx xxxx, xxxxx toho, xx xxxxxxx později:
|
x) |
xx xxx xxxxxx xx xxxxxxx zprávy; |
|
x) |
ve xxxxx xxxxxxxxx v příloze III. |
Agentura xxxxxxxx stanovisko Xxxxxx xx 270 xxx xx xxxxxxxx xxxxxxxx.
Xxxxxx 8
Xxxxxx látky, xxxxx xx xxxx xxxxxxxx
1. Xxx xxxxxxxx xxxxx xxxxxxxxxx xxxxx xx. 7 xxxx. 2 agentura xxxxxxx, xxx xxxxxx látka xxxxxxx xxxxxxx x xxxxxxxx xxxxxxxxx x xx. 10 xxxx. 1 xxxxxxxx (EU) č. 528/2012, x xxxx xxxxxx zmíní xx xxxx xxxxxxxxxx.
2. Xxxx jsou xxxxxxx xxxxxx 66 x 67 xxxxxxxx (XX) x. 528/2012, xxxxx xxx xxxxxxxx xxxxxxxx své xxxxxxxxxx Komisi, zveřejní xxxxxxxxx x xxxxxxx látkách, xxxxx se mají xxxxxxxx, xxxxx xxxxxxxxx 60 dnů; x xxxx době mohou xxxxxxxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx x xxxxxxxxxx xxxxxxxxx. Xxxxxxxx xxxxxxxx xxxxxxxxx náležitě xxxxxxxx x xxxxxxxxx xxxx xxxxxxxx svého xxxxxxxxxx.
3. Pokud xx xxxxxx xxxxx xxxxxxxxx a splňuje xxxxx x xxxxxxxx xxxxxxxxxxx x xx. 10 xxxx. 1 xxxxxxxx (XX) x. 528/2012, xxxx xxx xxxxxxxx za látku, xxxxx xx xx xxxxxxxx, x xxxxxxxx xxxxxxxx x xxxxxxx s čl. 89 odst. 1 xxxxxx pododstavcem xxxxxxxxx xxxxxxxx.
Xxxxxx 9
Xxxxxxxxxx Xxxxxx
Xx xxxxxxxx stanoviska agentury xxxxx čl. 7 xxxx. 2 Xxxxxx xxx xxxxxxxxxx xxxxxxxx připraví xxxxx xxxxxxxxxx pro xxxxxxx xxxxx xx. 89 xxxx. 1, xxxx případně xxxxx xx. 28 odst. 1 nařízení (XX) č. 528/2012.
XXXXXXXX 3
ZMĚNY XXXXX XXXXXXXX XXXXXXXX
Xxxxxx 10
Připojení xxxx nahrazení účastníků xx xxxxxxxx xxxxxx
1.&xxxx;&xxxx;&xxxx;Xxxx xxxxxxxxx je xxxxx xx xxxxxxxx xxxxxx xxxx stávajícím účastníkem x potenciálním xxxxxxxxxx xxxxxxx nebo sdílet xx předpokladu, xx xx xxxxxxxxxxx xxxxxxxx xxxxx odvolávat xx xx xxxxxxx xxxxx xxxxxxxxxx xxxx uvedené xxxxxxxxxx xxxxxxxxxx.
2.&xxxx;&xxxx;&xxxx;Xxxxxxxx xxx xxxxx xxxxxx článku xxxxxxxxxxx xxxxxxxx společně xxxxxxxxxxx x&xxxx;xxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxx rejstříku xxx xxxxxxxx xxxxxxxxx xxxxxxxxx x xxxxxx 71 xxxxxxxx (XX) x. 528/2012 (dále xxx „xxxxxxxx“) x&xxxx;xxxxxxxx musí xxxxxxxxx všechna xxxxxxxxx xxxxxxxx x xxxxxxxx.
3.&xxxx;&xxxx;&xxxx;Xx xxxxxxxx xxxxxxxx splňujícího xxxxxxxxx xxxxx xxxxxxxx 2 agentura xxxxxxxxxxx xxxxxxxxx x&xxxx;xxxxxxxxx xxxxxxxx xx xxxxxxxxxx xxxxxxxxx.
4.&xxxx;&xxxx;&xxxx;Xxxxx xxxxxxx na území Xxxx, xxxxx xxxxxxxx xxxx xxxxxxxxx nebo xx xxxxxxxxx x xxxxxxxxxxx xxxxx xxxxxx článku, xx xxx účely xxxxxx 95 xxxxxxxx (XX) x.&xxxx;528/2012 xxxxxxxxxx xx xxxxx, která xxxxxxxxxx dokumentaci nebo xxxxxxxx k přístupu x xxxxxxxxxxx.
Xxxxxx 11
Odstoupení xxxxxxxxx
1. Xx xx xx xx, xx účastník odstoupil x účasti xx xxxxxxx kombinace xxxxx x xxxx xxxxxxxxx v programu xxxxxxxx, x xxxxxx xxxxxxxxx:
|
x) |
xxxxx informoval xxxxxxxx xxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxxxxxxx rejstříku x xxxx záměru xxxxxxxxx; |
|
x) |
xxxxx xxxxxxxxxxx xxxxxx xx lhůtě uvedené x xx. 3 odst. 2; |
|
c) |
xxxxx xxxx xxxxxx xxxx xxxxxxxxx xxxxx xx. 4 odst. 1, xx. 4 xxxx. 4 xxxx xx. 5 xxxx. 4; |
|
x) |
xxxxx xxxxxxxxxxx xxxxxxxxxx informace xx xxxxxxx xxxxxxxxx x xx. 6 xxxx. 5; |
|
x) |
xxxxx xxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxx nebo agentuře. |
2. Odstoupení xx xxxxxxxx xx xxxxxxxxx xxxx, xxxxx x xxxx xxxxxxx xx datu, xxx xxxxxxxxx xxxxxxxxx orgán xxxxxxxxx žadateli xxxxxx xxxxxxxxxxx orgánu podle xx. 6 odst. 4 xxxxxx xxxxxxxx.
Xxxxxx 12
Xxxxxxxx včasného xxxxxxxxxx
1. Xxxxx je o xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx příslušný xxxxx, xxx nikoli xxxxxxxx, xxxxxxxxx xx hodnotící xxxxxxxxx xxxxx xxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx.
2. Xxxxx xx x xxxxxxx odstoupení xxxxxxxxxxx xxxxxxxx, xxxxxxxxxxx xxxxxxxxx x xxxxxxxxx týkající xx xxxxxxxxxx účastníka.
3. Xxxxx x xxxxxxxx xxxxxxxx včas xxxxxxxxxx xxxxxxx účastníci xxxxxxxxxxx tutéž xxxxxxxxx xxxxx a typu přípravku x xxxxx xxxx xxxx xxxxxxxxx xxx xxxxxxxx xxxxxxxxx xxxxx xxxxxxxx, xxxxxxxxx o xxx xxxxxxxx prostřednictvím xxxxxxxxx Xxxxxx.
Xxxxxx 13
Xxxx xxxxxxxx xxxxxxxxx xxxxx
1. Xxxxx xxxxxxxxx xxxxxxxxx xxxxxx xxxxx xxxxxxxx vyvodit xxxxxx xxxxxxxx xx látky, xxx xxxx xxxxxxx x xxxxxxx XX, xxxxxxxxx xxxxxxxxx xxxxx xx konzultaci x dotyčným účastníkem xxxxxxx novou xxxxxxxx xxxxx. Xxxxxxxxx xxxxxxxxx xxxxx o tom xxxxxxxxx xxxxxxxx.
2. Xxxxxxxx x xxxxxxxxx aktualizuje xxxxxxxxx týkající xx xxxxxxxx látky.
Xxxxxx 14
Převzetí xxxx xxxxxxxxx
1. Xxxxxxxx xxxxxxxx otevřenou xxxxx x xxxxxxxx xxxx účastníka pro xxxxxxxxx látky a typu xxxxxxxxx, xxxxx xxxxxxx xxxxx x xxxxxx xxxxxxx:
|
x) |
xxxxx xxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxx xxxxxxxxxx xxxxx článku 11 x xxxxxx xxxx účastníka xxx danou xxxxxxxxx xxxxxx xxxxxxx převzata; |
|
x) |
xx xxxxxxx xxxx xxxxxxxx xxxxx xxxxxx 13; v tomto xxxxxxx xx xxxxx xxxx xxxxx xx xxxxx, xx xxxxxx xx xxxxxxxx xxxxxxxxx identita x xxxxxxx XX, xxx xxxxxxx xxxx xxxxxxxx xxxxx. |
2. Do dvanácti xxxxxx xxx xxx zveřejnění xxxxx xxxxxxxx 1 xxxx xxxxxxxxx osoba xxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxx xxxxxx 17.
3. Xx xxxxxxxx xxxxxx xx xxxx xxxxxx xxxxxx xxxxxxxx x xxxxxxxx může xxxxxxxxx xxxxx xxxxxxx xxxxxxxxx xxxxx x xxxx přípravku xxxxxxxxx do části 2 xxxxxxx XX podle xxxxxx 17.
Xxxxxx 15
Kombinace látky x xxxx xxxxxxxxx xxxxxxxxx xxx zařazení xx xxxxxxxx xxxxxxxx
Xxxxx xxxxxxxx xxxxxxxxx, xxxxx xxxxx xx xxxxxxx xxxxxxxxxx xxxxxxxx (XX) x. 528/2012 x xx xxxxxx xx xxx, xxxxxxx ze xxxxxxxxx xxxxxx xxxxx, xxx xxxx xxxxxxxxx xxx xxxxxxxx do programu xxxxxxxx xxx tento xxx přípravku x xxxx zařazena xx xxxxxxx I uvedeného xxxxxxxx, xxxx látku xxxxxxxx nebo xx x xx vyrábí, xx uvedená xxxxx xxxxxxxxx xxx zařazení xx xxxxxxxx xxxxxxxx xxx xxxxxxxxx typ xxxxxxxxx xx xxxxxxx xxxxxxxxx z těchto xxxxxx:
|
x) |
xxxxx uvádějící xxxxxxx xx xxx se spoléhala xx pokyny nebo xxxxxxx xxxxxxxxxx vydané Xxxxxx nebo příslušným xxxxxxx jmenovaným x xxxxxxx x xxxxxxx 26 xxxxxxxx 98/8/XX nebo xxxxxxx 81 xxxxxxxx (EU) x. 528/2012, xxxxx xx xxxxxxx xxxxxxxxxx opodstatněných xxxxxx xxxxx xxxxxxx xxxxxx xx xxxxxxxxxx x xxxxxxxxxxx, xx xxxxxxx xxx xxxxx z působnosti xxxxxxxx 98/8/XX xxxx xxxxxxxx (XX) č. 528/2012, nebo xx xxx xxxxxxxxx xxx xxxxxxxxx xxxxxx x xxxxxxxxx, xxx xxxxx xxxx xxxxxx xxxxx oznámena, x xxxxx xxxx xxxxxxx xxxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxxxxxx v xxxxxxxxxx přijatém xxxxx xx. 3 xxxx. 3 xxxxxxxx (EU) x. 528/2012 xxxx v nových, xxxxxxxxx xxxxxxxx zveřejněných Xxxxxx; |
|
x) |
xxxxx xxxxxxxxx odchylky pro xxxxxxxxx x xxxxxx stanovené x xxxxxx 6 xxxxxxxx (XX) x. 1451/2007; |
|
x) |
biocidní přípravek xxxxx xxxxx nařízení (XX) x. 528/2012 x xxxxxxxxx typu xxxxxxxxx, xxx xxxx bylo xxxxx xxxxxxxx 98/8/XX, x xxxxxxxx xxxxx xxxxxxxxxx těchto xxxx xxxxxxxxx x xxxxxxxx xxxxx xxxxxxxxx xx xxxxxxxx xxxxxxxx pro xxxxxxx xxx xxxxxxxxx, xxx xxxxxx xxx xxxx. |
Xxxxxx 16
Prohlášení x xxxxx xx xxxxxxxx
1. Xxxxxxxxxx x xxxxx xxxxxxx xxxxx, xxxxx je xxxxxxxxx xxx xxxxxxxx do programu xxxxxxxx podle xxxxxx 15, předkládá xxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxxx osoba, xxx xx xxxxx xxxxxxx kombinaci xxxxx x xxxx xxxxxxxxx, jednomu x xxxxxxxxxxxxx příjemců:
|
x) |
Xxxxxx xxxxxxxxxx xxxxxxx xxxxxx xx zveřejnění xxxxxxxxxx xxxx xxxxxx xxxxxxxxx x xx. 15 xxxx. x); |
|
x) |
agentuře xxxxxxxxxx 30. října 2015 x případech xxxxxxxxx x xx. 15 písm. b); |
|
c) |
Komisi xxxxxxxxxx 30. xxxxx 2015 x případech xxxxxxxxx v xx. 15 xxxx. x). |
2. Xxxxxxxxxx xxxx obsahovat xxxxxxxxxx xxxxxxxxx látky x xxxx xxxxxxxxx. X xxxxxxxxx xxxxxxxxx v čl. 15 xxxx. x) xxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxxxxx odůvodnění, x nějž xxxxxxx, xx xxxx xxxxxxx xxxxxxx xxxxxxxx x xxx xxxxxxx.
3. Pokud bylo xxxxxxxxxx xxxxxxx x xxxxxxx xxxxxxxx x xx. 15 xxxx. x) xxxx x) x Xxxxxx xxxxxxx xx xxxxxxxxxx x xxxxxxxxx xxxxx x xxxxxx, že xxxxxxxx 6 xxxx xxxxxxxxxx, x xxxxxxxx, že xxxx xxxxxxx xxxxxxxx xxx xxxxxxxx xxxxxxx x xx. 15 písm. a), xxxxxxx x xxx xxxxxxxx.
4. Xxxxx xxxx prohlášení xxxxxxx v případě xxxxxxxx x xx. 15 xxxx. b) xxxx xxxxx Xxxxxx xxxxxxxxxxx xxxxxxxx podle xxxxxxxx 3, xxxxxxxx xxxxxxxx xxxx informaci elektronickými xxxxxxxxxx s uvedením xxxxxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx. Pro xxxxx xxxxxx nařízení xx xxxxxxxxxx podle xx. 3x xxxx. 3 třetího xxxxxxxxxxx xxxxxxxx (XX) x. 1451/2007 xxxxxxxx xx xxxxxxxxxx xxxxx xxxxxx odstavce.
5. Xxxxxxxxx xxxxx, xxxxx xx xxxxx xxxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx, xxx může xxxxxx xxxxx článku 17 xx xxxxx xxxxxx xxx xxx xxxxxxxxxx xxxxx xxxxxxxx 4.
6. X xxxxxxxxx xxxxxxxxx x čl. 15 písm. x) a c) se xxxxxxxxx látky a typu xxxxxxxxx xxxxxxxx xx xxxxxxxxx xxxxxxxxxx a není xxxxxxxxx x xxxxxxx xxxxxxxx, xxxxx xxxx xxxxxxx tyto xxxxxxxx:
|
x) |
xxxxxxxxx xxxxxx xxxxx xx xxx zařazena xx xxxxxxxx xxxxxxxx; |
|
x) |
xxxxxxxxxxx předložená hodnotícímu xxxxxxxxx státu xxx xxxxxxxxxx xxxxxxx xxxxx xxx obsahuje xxxxxxx xxxxx, xxxxx jsou xxxxxxxx xxx hodnocení xxxx xxxxxxxxx; |
|
x) |
xxxxxxxx, který xxxxxxxxx xxxxxxxx xxxxxxxxxxx, xxxxx, xx xx xxxxx x xxxxxxx xxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx. |
Xxxxxx 17
Postup oznámení
1. Xxxxxxxx xxxxx čl. 14 odst. 2 x 3 xxxx xx. 16 xxxx. 5 xx xxxxxxxxxxx agentuře prostřednictvím xxxxxxxxx.
2. Xxxxxxxx xxxx xxx xxxxxxxxxx xx xxxxxxx XXXXXX. Musí xxxxxxxxx xxxxx xxxxxxx v xxxxxxx X.
3. Pokud xxxx x xxxxxxx XX xxx xxxxxxxx xxxxxxx xxxxx uveden xxxxxxxxx xxxxxxxxx xxxxx, xxxxxxxxx xxxxxxxxxxx xxxxxxxx x xxxxx xxx vybraného xxxxxxxxxxx xxxxxx, který xx jmenován x xxxxxxx x xxxxxxx 81 nařízení (XX) x. 528/2012, a poskytne písemné xxxxxxxxx dokládající, že příslušný xxxxx xxxxxxxx x xxx, xx xxxxxxxxxxx xxxxxxx.
4. Xx xxxxxxxx xxxxxxxx x xxx uvědomí xxxxxxxx Komisi x xxxxxxxxxxxx xxxxxxxxx x xxxxxxxxxx xxxxxxxxx podle xxxxxxxx (XX) č. 564/2013. Jestliže xxxxxxxxxxx xxxxxxxx xxxxxxxx xx 30 xxx xx xxxxxxx xxxxxxx xxxxxxxxx, agentura xxxxxxxx xxxxxxx a uvědomí x tom xxxxxxxxxxxx x Komisi.
5. Xx xxxxxxxx xxxxxxxx xxxxxxxx xx 30 xxx xxxxx, xxx xxxxxxxx vyhovuje xxxxxxxxxx uvedeným v xxxxxxxx 2. Xxxxx xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxx, xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxx x xxxxx 30 dnů, xxx své xxxxxxxx xxxxxxx xxxx opravil. Xx xxxxxxxx této 30xxxxx xxxxx agentura xx 30 dnů xxx xxxxxxxx, xx xxxxxxxx vyhovuje xxxxxxxxxx xxxxxxxx 2, nebo xxxxxxxx xxxxxxx, x xxx xxxxxxxxxx xxxxx xxxxxxxxxxxx x Xxxxxx.
6. X xxxxxxx s článkem 77 xxxxxxxx (XX) x. 528/2012 proti xxxxxxxxxxx agentury xxxxx xxxxxxxx 4 xxxx 5 xxxxx opravný xxxxxxxxxx.
7. Xxxxx xxxxxxxx xxxxxxxx xxxxxxxxxx podle odstavce 5:
|
x) |
x xxxxxxx, že bylo xxxxxxxx předloženo xxxxx xx. 14 odst. 2 xxxx 3, xxxxxxxx xxxxxxxxxx xxxxxxxxxxx informace v xxxxxxxxx týkající se xxxxxxxxxx xxxxxxxxx x xxxxxxxx identity xxxxx; |
|
x) |
x xxxxxxx, že oznámení bylo xxxxxxxxxx xxxxx xx. 16 xxxx. 5, xxxxxxxx xxxxxxxxxx xxxxxxxxx Xxxxxx, že xxxxxxxxxx bylo xxxxxxxx. |
Xxxxxx 18
Zařazení xx xxxxxxxx xxxxxxxx
Xxxxx xx xxxxxxxxx látky x xxxx xxxxxxxxx xxxxxxxxxx xx xxxxxxxxx v souladu s čl. 16 xxxx. 6 nebo xxxxx xxxxxxxx xxxxxxxxx Komisi x xxxxxxxx xxxxxxxxx x souladu x xx. 17 xxxx. 7 xxxx. x), xxxxxx Xxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx xx xxxxxxxx přezkumu.
Xxxxxx 19
Xxxxxxxxx x xxxxxxx, xxxxx xxxxxx xxxxxx xxxxxxxxxxx x xxxxx programu xxxxxxxx
Pokud xxxxxx xx xxxxx xxxxxxxxx x xx. 16 odst. 5 xxxxxxxx xxxxx oznámení xxxx xxxxx byla oznámení xxxxxxx ve xxxxxxxx xxxxxx přijata a následně xxxxxxxxx xxxxxxxxx xxxxx xx. 17 xxxx. 4 xxxx 5, xxxxxxxx o tom xxxxxxxxx xxxxxxx státy xxxxxxxxxxxxxxx xxxxxxxxx x xxxxxxxx xxxx informaci elektronickou xxxxxx.
Xxxxxx 20
Xxxxxxxxxx Xxxxxx x xxxxxxx, xxxxx xxxxxx xxxxxx xxxxxxxxxxx x rámci xxxxxxxx xxxxxxxx
Xxxxxx připraví xxxxx xxxxxxxxxx x xxxxxxxxxxx xxxxx xx. 89 xxxx. 1 xxxxxxx xxxxxxxxxxx xxxxxxxx (XX) č. 528/2012 x xxxxxx xxxxxxxxx:
|
x) |
xxxxx xxxxxxxx xxxxxxxxx Xxxxxx x xxxxxxx odstoupení xxxxxxxxx xxxxx čl. 12 xxxx. 3 xxxxxx xxxxxxxx; |
|
x) |
xxxxx xxxxx osoba xxxxxxxx xxxxxxxx xx xxxxxxx xxxxxxxxxxx x xx. 14 xxxx. 2 xxxx 3 xxxxxx xxxxxxxx xxxx pokud bylo xxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxx xx. 17 odst. 4 xxxx 5; |
|
x) |
xxxxx xxxx xxxxxxxx předloženo xx xxxxx xxxxxxxxx x xx. 14 odst. 2 xxxx 3 tohoto xxxxxxxx x xxxx xxxxxxxx xxxxxxxxx xxxxx čl. 17 xxxx. 5 xxxxxx nařízení, xxx identita látky x xxxxxxxx zahrnuje pouze xxxx xxxxxxxxx xxxxxxxx x xxxxxxx XX xxxxxx xxxxxxxx. |
V případě xxxxxxxx x xxxxxx pododstavci xxxx. x) xx xxxxx rozhodnutí x xxxxxxxxxxx xxxxxxxx xx xxxxxx xxxxx, xx xxxxxx xx xxxxxxxx stávající xxxxxxxx x xxxxxxx XX tohoto xxxxxxxx, xxxxx xxxxxx xxxxxxxx xxxx jakékoli xxxxxxxxxx x xxxxxxxxx.
XXXXXXXX 4
PŘECHODNÁ XXXXXXXX
Xxxxxx 21
Xxxxxxxxx xxxxxxxx xxx xxxxx uvedené x&xxxx;xxxxxx&xxxx;15
1.&xxxx;&xxxx;&xxxx;Xxxxxxx xxxx xxxx xxxxxxxxxx x&xxxx;xxxxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxx xxxx praxe xxxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxxxx xxxxxxxxxx přípravku, xxxxx xxxxxxx xx xxxxxxxxx xxxxxx xxxxx xxxxxxx x čl. 15 xxxx. x) x x), xxxx xxxxx xxxxxxxx xxxx x xx vzniká. X xxxxxx xxxxxxxxx:
|
x) |
xxxxx xxx xxxxxxxx xxxxxxxxx xxxxxx xxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxx xx&xxxx;24 xxxxxx xx xxxx xxxxxx tohoto xxxxxxxx v platnost; |
|
b) |
stávající zásoby xxxxxxxxxx přípravku xxxxx xxx xxxx využívány xx&xxxx;30 měsíců xx xxx xxxxxx xxxxxx xxxxxxxx v platnost. |
2. Členský xxxx xxxx xxxxxxxxxx v uplatňování xxxxx xxxxxxxxxxx xxxxxxx xxxx praxe dodávání xx&xxxx;xxx x&xxxx;xxxxxxxxx xxxxxxxxxx xxxxxxxxx, xxxxx xxxxxxx xx xxxxxxxxx xxxxxx xxxxx uvedené x xx. 15 písm. x), tuto xxxxx xxxxxxxx nebo z xx vzniká. X xxxxxx xxxxxxxxx:
|
x) |
xxxxx xxx xxxxxxxx xxxxxxxxx xxxxxx xxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxx xx&xxxx;24 měsíců xx xx x dále xxxxxxxxx xxxxxxxx, která xxxxxxx xxxxxxx:
|
|
b) |
stávající xxxxxx xxxxxxxxxx xxxxxxxxx xxxxx xxx dále xxxxxxxxx xx&xxxx;30 xxxxxx xx té z xxxx uvedených xxxxxxxx, xxxxx nastane xxxxxxx:
|
3.&xxxx;&xxxx;&xxxx;Xxxxxxx xxxx xxxx xxxxxxxxxx x&xxxx;xxxxxxxxxxx svého xxxxxxxxxxx xxxxxxx nebo xxxxx xxxxxxxx na trh x&xxxx;xxxxxxxxx biocidního přípravku, xxxxx xxxxxxx xx xxxxxxxxx účinné xxxxx xxxxxxxxxx xxxxxxxxx xxxxx xx. 16 odst. 4 xxx xxxxxxxxx xxx výrobku, xxxx xxxxx obsahuje xxxx x xx vzniká. X xxxxxx xxxxxxxxx:
|
x) |
xxxxx xxx biocidní xxxxxxxxx xxxxxx dodáván xx&xxxx;xxx x&xxxx;xxxxxxx xx&xxxx;xxxxxxxx xxxxxx xx datu, kdy xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxx 19 x |
|
x) |
xxxxxxxxx xxxxxx xxxxxxxxxx přípravku xxxxx xxx xxxx xxxxxxxxx xx&xxxx;xxxxxxxx xxxxxx xx xxxx uvedeného xxxxxxxxxx. |
Xxxxxx 22
Nezbytná xxxxxxx
1. Aniž xx xxxxxx xx. 55 xxxx. 1 nařízení (XX) x. 528/2012, do osmnácti měsíců xx xxxx rozhodnutí x xxxxxxxxxxx xxxxxxxxx xxxxxx xxxxx, xxxxx xxxxxxx xxxx xxxxxxxx xxxx xxxxxxxxx xxxxxxx látku xx xxxxxxxxx z důvodů uvedených x xx. 5 xxxx. 2 xxxxxx pododstavci xxxx. b) xxxx x) nařízení (EU) x. 528/2012, xxxxx členský xxxx může xxxxxxxxx Xxxxxx odůvodněnou žádost x xxxxxxxx xx xx. 89 odst. 2 xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx.
2. Xxxxxxxx xxxxxxx stát xxxxxxxx xxxxxxxxxxx xxxxxx xxxxxxxx xxxxxxxxxxxxxxx rejstříku. Xxxxx žádost xxxxxxxx xxxxxxx xxxxxxxxx, žádající xxxxxxx stát xxxx xxxxxxx xxxxxxxxx xxxxxxxxx xxxxx.
3. Xxxxxxxx xxxxxxxx xxxxxx xxxx případně nedůvěrnou xxxxx elektronickými xxxxxxxxxx. Xxxxxxx xxxxx xxxx xxxx xxxxx mohou xxxxx xxxxxxxxxx xx xxxxx 60 xxx xx xxxxxxxxxx.
4. Xx xxxxxxx xxxxxxxxxx xxxxxxxxxx může Xxxxxx xxxxxxx xxxxxxxx od čl. 89 xxxx. 2 xxxxxxx xxxxxxxxxxx xxxxxxxx (EU) x. 528/2012, xxxxx xxxxxx uvádět xxxxxxxx xxxxxxxxx, xxx xxxxxxxxx z xxxx xxxxx, obsahují ji xxxx x ní xxxxxxxx, na xxx xxxxxxxxxx členského xxxxx x xxxxxxxx je x xxxxx xxxxxxxx xxxxx v souladu x xxxxxxxxxxxxxx xxxxxxxx xxxxxxxx x x xxxxxxxx podmínek xxxxxxxx 5 a veškerých xxxxxxx xxxxxxxx xxxxxxxxx Xxxxxx.
5. Xxxxxxx xxxx, xxxxx je xxxxxxxx xxxxxxxx:
|
x) |
xxxxxxx, že další xxxxxxxxx xxxx xxxxxxx xx xxxxxx případy x xxxxxxx xxxx, kdy xxxx plněny xxxxxxxx xxxxxxxx 1; |
|
x) |
xxxxxx vhodná xxxxxxxx xx xxxxxxxx xxxxx, xxx xxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxx, xxxxxx xxxx xxxxxxxxx xxxxxxxxx; |
|
c) |
zajistí, xxx xx hledala xxxxxxxxxxxx xxxxxx nebo aby xxxx xxxx xxxx xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxx x xxxxxxxxx xxxxxx xxxxx x xxxxxxx xxxxxxx 7 xxxxxxxx (XX) x. 528/2012. |
XXXXXXXX 5
XXXXXXXXX XXXXXXXXXX
Xxxxxx 23
Xxxxxxx
Xxxxxxx se nařízení (XX) x. 1451/2007.
Xxxxxx xx xxxxxxx xxxxxxxx xx považují za xxxxxx na toto xxxxxxxx.
Xxxxxx 24
Vstup x xxxxxxxx
Xxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx xxxx po xxxxxxxxx x Xxxxxxx věstníku Xxxxxxxx xxxx.
Xxxx nařízení xx xxxxxxx x celém xxxxxxx x přímo xxxxxxxxxx xx všech xxxxxxxxx státech.
X Xxxxxxx xxx 4. xxxxx 2014.
Xx Komisi
xxxxxxxx
Xxxx Xxxxxx XXXXXXX
(1)&xxxx;&xxxx;Xx. xxxx. L 167, 27.6.2012, x. 1.
(2)&xxxx;&xxxx;Xxxxxxxx Xxxxxx (XX) x. 1451/2007 xx xxx 4. xxxxxxxx 2007 x xxxxx xxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxx x xx. 16 xxxx. 2 xxxxxxxx Evropského xxxxxxxxxx a Rady 98/8/XX o xxxxxxx xxxxxxxxxx xxxxxxxxx xx xxx (Xx. věst. X 325, 11.12.2007, x. 3).
(3)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx 98/8/XX xx xxx 16. xxxxx 1998 o xxxxxxx xxxxxxxxxx xxxxxxxxx xx trh (Xx. xxxx. X 123, 24.4.1998, s. 1).
(4) Rozsudek Xxxxxxxx xxxxx (xxxxxxx xxxxxx) ze xxx 1. března 2012 (xxxxxx x xxxxxxxxxx x xxxxxxxxx xxxxxx: Xxxxxxxxxxx Xxxxxxx – Xxxxxxx) – Xöxx GmbH xxxxx Xxxxx XxxX (uvádění xxxxxxxxxx přípravků xx xxx – xxxxxxxx 98/8/XX – xx. 2 xxxx. 1 xxxx. x) – xxxxx „xxxxxxxx xxxxxxxxx“ – xxxxxxxxx, který xxxxxxxxx vločkování xxxxxxxxxx xxxxxxxxx, xxxx xx xxxx, xxxxxxxx xxxx xxxxxxxxxxx), X-420/10.
(5)&xxxx;&xxxx;Xxxxxxxxx xxxxxxxx Komise (XX) x.&xxxx;88/2014 xx xxx 31.&xxxx;xxxxx 2014, xxxxxx xx stanoví xxxxxx xxx xxxxx xxxxxxx X&xxxx;xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (XX) x.&xxxx;528/2012 o dodávání biocidních xxxxxxxxx na trh x&xxxx;xxxxxx xxxxxxxxx (Úř. xxxx. X 32, 1.2.2014, s. 3).
(6) Nařízení Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 1272/2008 xx xxx 16. xxxxxxxx 2008 o klasifikaci, xxxxxxxxxx x xxxxxx xxxxx x xxxxx, x xxxxx a xxxxxxx směrnic 67/548/XXX x 1999/45/XX x x změně xxxxxxxx (XX) č. 1907/2006 (Xx. xxxx. X&xxxx;353, 31.12.2008, x. 1).
(7)&xxxx;&xxxx;Xxxxxxxxx xxxxxxxx Komise (XX) x.&xxxx;564/2013 xx xxx 18. června 2013 x&xxxx;xxxxxxxxxx x&xxxx;xxxxxxxx xxxxxxxxx Xxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxx xxxxx xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (XX) x.&xxxx;528/2012 x&xxxx;xxxxxxxx biocidních přípravků xx xxx x&xxxx;xxxxxx xxxxxxxxx (Xx.&xxxx;xxxx.&xxxx;X 167, 19.6.2013, s. 17).
(8)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx (XX) x. 1907/2006 ze xxx 18. xxxxxxxx 2006 x xxxxxxxxxx, xxxxxxxxx, povolování x xxxxxxxxx xxxxxxxxxx látek, x zřízení Evropské xxxxxxxx xxx xxxxxxxx xxxxx, o xxxxx xxxxxxxx 1999/45/XX x x zrušení nařízení Xxxx (XXX) x.&xxxx;793/93, xxxxxxxx Xxxxxx (XX) x. 1488/94, xxxxxxxx Xxxx 76/769/XXX x xxxxxxx Xxxxxx 91/155/XXX, 93/67/XXX, 93/105/ES x 2000/21/XX (Xx. věst. X 396, 30.12.2006, x. 1).
XXXXXXX X
Informace xxxxxxxxxx xxx xxxxxxxx xxxxx xxxxxx 17
Oznámení xxxxx xxxxxx 17 xxxxxxxx xxxx xxxxxxxxx:
|
1) |
xxxxx, xx xxxxx xx xxxxxxxxx xxxxxxx xxxxxx ve smyslu čl. 3 xxxx. 1 xxxx. x) nařízení (XX) x. 528/2012; |
|
2) |
xxxxx o xxxx/xxxxxx xxxxxxxxx, na xxxxx/x xx xxxxxxxx xxxxxxxx; |
|
3) |
xxxxxxxxx x xxxxx studiích, xxxxx byly zadány xxx účely xxxxxxx x xxxxxxxxx xx zařazení xx xxxxxxx X xxxxxxxx (EU) x. 528/2012, xxxxx x xxxxxxxxx xxxxx xxxxxx xxxxxxxxx; |
|
4) |
xxxxxxxxx xxxxxxx x oddílech
|
|
5) |
xxxxx xxxx xxxx oznámení xxxxxxx x xxxxxxx xxxxxxxx x xx. 15 písm. x), xxxxx, že látka xxxx xx xxxx xxxx xxxxxx xxxxx biocidního přípravku xxxxxxxxxxx xx xxxxxxxxxxx typu xxxxxxxxx x xxx xxxxxxxx xxxx xxxxxxxxxx rozhodnutí xxxx pokynů xxxxxxxxx xx xxxxxxxx xxxxxxx. |
XXXXXXX XX
XXXXXXXXX XXXXX X XXXX PŘÍPRAVKU XXXXXXXX XX XXXXXXXX XXXXXXXX DNE 4. XXXXX 2014
XXXX 1
Xxxxxxxxx xxxxxx látky x xxxx xxxxxxxxx podporované xx dni 4. xxxxx 2014, x xxxxxxxx xxxxxxxxxx xxxxxx nanomateriálů xxx xxxx, xxxxx xxxx výslovně uvedeny x xxxxxxxxx 1017 a 1019.
|
Číslo xxxxxxx |
Xxxxx látky |
Xxxxxxx stát xxxxxxxxx |
Xxxxx ES |
Xxxxx XXX |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
17 |
18 |
19 |
21 |
22 |
|
1 |
xxxxxxxxxxx |
DE |
200-001-8 |
50-00-0 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
6 |
5-{[2-(2-butoxyethoxy)ethoxy]methyl}-6- xxxxxx-1,3-xxxxxxxxxxx (xxxxxxxxxxxxxxxx/XXX) |
XX |
200-076-7 |
51-03-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
9 |
xxxxxxxx |
XX |
200-143-0 |
52-51-7 |
|
x |
|
|
|
x |
|
|
x |
|
x |
x |
|
|
|
|
|
x |
|
29 |
xxxxxxxxxxx |
XX |
200-431-6 |
59-50-7 |
x |
x |
x |
|
|
x |
|
|
x |
|
|
|
x |
|
|
|
|
|
|
36 |
xxxxxxx |
XX |
200-578-6 |
64-17-5 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
37 |
xxxxxxxx xxxxxxxx |
XX |
200-579-1 |
64-18-6 |
|
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
40 |
xxxxxx-2-xx |
XX |
200-661-7 |
67-63-0 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
43 |
kyselina xxxxxxxxxx |
NL |
200-712-3 |
69-72-7 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
45 |
propan-1-ol |
DE |
200-746-9 |
71-23-8 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
52 |
xxxxxxxxxxx |
N |
200-849-9 |
75-21-8 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
60 |
kyselina xxxxxxxxx |
XX |
201-069-1 |
77-92-9 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
69 |
xxxxxxxxx xxxxxxxx/2-xxxxxxxxxxxxxxx xxxxxxxx |
XX |
201-180-5 |
79-14-1 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
70 |
xxxxxxxx xxxxxxxxxxxx |
XX |
201-186-8 |
79-21-0 |
x |
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
71 |
X-(+)-xxxxxx kyselina |
DE |
201-196-2 |
79-33-4 |
|
x |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
79 |
2-xxxxxxxxxxx-8,9-xxxxxxxxx-1,2,6,6x,12,12x-xxxxxxxxxxxxxxxxx[3,4-x]xxxx[2,3-x]xxxxxxx-6-xx (xxxxxxx) |
XX |
201-501-9 |
83-79-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
85 |
xxxxxxxxx |
XX |
201-782-8 |
87-90-1 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
92 |
xxxxxxx-2-xx |
ES |
201-993-5 |
90-43-7 |
x |
x |
x |
x |
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
113 |
xxxxxxxxxxxxx/3-xxxxxxxxx-2-xxxx (xxxxxxxxxxxxx) |
XX |
203-213-9 |
104-55-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
117 |
xxxxxxxx |
XX |
203-377-1 |
106-24-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
122 |
xxxxxxx |
XX |
203-474-9 |
107-22-2 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
133 |
xxxx-2,4-xxxxxxx xxxxxxxx (kyselina xxxxxxx) |
XX |
203-768-7 |
110-44-1 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
136 |
xxxxxxxx (glutaraldehyd) |
XX |
203-856-5 |
111-30-8 |
|
x |
x |
x |
|
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
154 |
chlorofen |
X |
204-385-8 |
120-32-1 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
171 |
2-fenoxyethan-1-ol |
XX |
204-589-7 |
122-99-6 |
x |
x |
|
x |
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
172 |
xxxxxxxxxxxxxxx-xxxxxxx/1-xxxxxxxxxxxxxxxx-1-xxx-xxxxxxx |
XX |
204-593-9 |
123-03-5 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
179 |
xxxx uhličitý |
FR |
204-696-9 |
124-38-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
180 |
(xxxxxxx-xxxxxxxxx) – natrium-dimethylarsinát |
XX |
204-708-2 |
124-65-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
185 |
xxxxxxxxxxxxxx, xxxxx xxx (xxxxx xxx xxxxxxxxxxxxxxx – chloramin X) – (X-xxxxx-4-xxxxxxxxxxxx-1-xxxxxxxxxx |
ES |
204-854-7 |
127-65-1 |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
187 |
kalium-dimethyldithiokarbamát |
XX |
204-875-1 |
128-03-0 |
|
|
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
188 |
xxxxxxx-xxxxxxxxxxxxxxxxxxxxxx |
XX |
204-876-7 |
128-04-1 |
|
|
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
195 |
xxxxxxx-xxxxxxx-2-xxxx |
XX |
205-055-6 |
132-27-4 |
x |
x |
x |
x |
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
198 |
N-[(trichlormethyl)sulfanyl]ftalimid (xxxxxx) |
XX |
205-088-6 |
133-07-3 |
|
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
206 |
xxxxxx |
XX |
205-286-2 |
137-26-8 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
210 |
xxxxxx-xxxxxxx |
XX |
205-293-0 |
137-42-8 |
|
|
|
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
227 |
2-(xxxxxxx-4-xx)xxxxxxxxxxxx (xxxxxxxxxxxx) |
ES |
205-725-8 |
148-79-8 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
|
235 |
xxxxxx |
DK |
206-354-4 |
330-54-1 |
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
|
|
|
239 |
xxxxxxxxxxxxx |
XX |
206-992-3 |
420-04-2 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
253 |
xxxxxxxxxx-3,5-xxxxxxxx-1,3,5-xxxxxxxxxx-2-xxxxx (xxxxxxx) |
BE |
208-576-7 |
533-74-4 |
|
|
|
|
|
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
279 |
N-[(dichlorfluormethyl)sulfanyl]-N′,N′-dimethyl-N-(4-methylfenyl)sulfonamid (xxxxxxxxxxxx) |
XX |
211-986-9 |
731-27-1 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
x |
|
|
283 |
xxxxxxxxx |
XX |
212-950-5 |
886-50-0 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
|
288 |
X-[(xxxxxxxxxxxxxxxxxx)xxxxxxxx]-X-xxxxx-X′,X′-xxxxxxxxxxxxxxxx (xxxxxxxxxxxxx) |
XX |
214-118-7 |
1085-98-9 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
x |
|
|
289 |
xxxxxxxxxxxx měďný |
FR |
214-183-1 |
1111-67-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
292 |
[(1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl)methyl]-trans-2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyklopropan-1-karboxylát (x-xxxxx-xxxxxxxxxxxx) |
XX |
214-619-0 |
1166-46-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
958 |
xxxxxxxx vápenatý/hydratované xxxxx/xxxxxx xxxxx |
XX |
215-137-3 |
1305-62-0 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
959 |
xxxx xxxxxxxx/xxxxx/xxxxxx xxxxx/xxxxxxxx xxxxx |
XX |
215-138-9 |
1305-78-8 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
306 |
xxxx xxxxx |
FR |
215-270-7 |
1317-39-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
315 |
xxxxx-2-xx-xxxxxxx |
HU |
215-661-2 |
1338-23-4 |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
321 |
monolinuron |
XX |
217-129-5 |
1746-81-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
330 |
X-(3-xxxxxxxxxxx)-X-xxxxxxxxxxxxx-1,3-xxxxxx (xxxxxx) |
XX |
219-145-8 |
2372-82-9 |
|
x |
x |
x |
|
x |
|
x |
|
|
x |
x |
x |
|
|
|
|
|
|
336 |
X,X′-xxxxxxxx-2,2′-xxxxxxxxxxxxxxxxxxxxxx (XXXXX) |
XX |
219-768-5 |
2527-58-4 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
339 |
1,2-xxxxxxxxxxxxxxx-3(2X)-xx (BIT) |
XX |
220-120-9 |
2634-33-5 |
|
x |
|
|
|
x |
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
341 |
2-methyltetrahydroisothiazol-3(2H)-on (MIT) |
XX |
220-239-6 |
2682-20-4 |
|
|
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
346 |
xxxxxxx-xxxxxxxxxxxxxxxxxx xxxxxxxx |
XX |
220-767-7 |
51580-86-0 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
345 |
xxxxxxx-xxxxxxxxxxxxxxxxxx |
XX |
220-767-7 |
2893-78-9 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
348 |
xxxxx(xxxxxxxxx)xxxxxxxxxxxxxxx-xxxxx-xxxxxx (XXX) |
PL |
221-106-5 |
3006-10-8 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
354 |
xxxxxxxxx |
XX |
222-182-2 |
3380-34-5 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
359 |
(xxxxxxxxxxxx)xxxxxxxxxx (xxxxxxx xxxxxxxx xxxxxxxxxxxxxx x xxxxxxxxxxxxxxxx (XXXxxx)) |
XX |
222-720-6 |
3586-55-8 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
365 |
xxxxxxx-2-xxxxx-1-xxxx, xxxxx xxx (xxxxxxxxx sodný) |
XX |
223-296-5 |
3811-73-2 |
|
x |
x |
|
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
368 |
1-(3-xxxxxxxxxx)-3,5,7-xxxxxx-1-xxxxxxxxxxxxxxx-xxxxxxx (XXXX) |
XX |
223-805-0 |
4080-31-3 |
|
|
|
|
|
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
377 |
1,3,5-xxxx(2-xxxxxxxxxxxx)xxxxxxxxx-1,3,5-xxxxxxx (XXX) |
XX |
225-208-0 |
4719-04-4 |
|
|
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
382 |
1,3,4,6-tetrakis(hydroxymethyl)hexahydroimidazo[4,5-d]imidazol-2,5-dion (XXXX) |
ES |
226-408-0 |
5395-50-6 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
387 |
xxxxxxxxxxxxxxxxx (XXX) |
XX |
227-062-3 |
5625-90-1 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
392 |
xxxxxxxx-xxxxxxxxxxxx |
XX |
228-652-3 |
6317-18-6 |
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
393 |
1,3-xxx(xxxxxxxxxxxxx)-5,5-xxxxxxxxxxxxxxxxxxxx-2,4-xxxx (DMDMH) |
XX |
229-222-8 |
6440-58-0 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
397 |
didecyldimethylamonium-chlorid (XXXX) |
XX |
230-525-2 |
7173-51-5 |
x |
x |
x |
x |
|
x |
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
401 |
xxxxxxx |
XX |
231-131-3 |
7440-22-4 |
|
x |
|
x |
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
403 |
xxx |
FR |
231-159-6 |
7440-50-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
405 |
xxxx xxxxxxxx |
XX |
231-195-2 |
7446-09-5 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
424 |
xxxxxx xxxxx |
XX |
231-599-9 |
7647-15-6 |
|
x |
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
432 |
xxxxxxxx xxxxx |
XX |
231-668-3 |
7681-52-9 |
x |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
434 |
xxxxxxxxxxxx |
XX |
231-711-6 |
7696-12-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
439 |
xxxxxxx xxxxxx |
XX |
231-765-0 |
7722-84-1 |
x |
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
444 |
7x-xxxxxxxxxxxx-1X,3X,5X-xxxxxxx[3,4-x]xxxxxx (XXXX) |
PL |
231-810-4 |
7747-35-5 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
450 |
xxxxxxxx xxxxxxxx |
XX |
231-853-9 |
7761-88-8 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
453 |
xxxxxxxxxxxxx xxxxx |
XX |
231-892-1 |
7775-27-1 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
455 |
xxxxxxxx xxxxxxxx |
XX |
231-908-7 |
7778-54-3 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
457 |
chlor |
XX |
231-959-5 |
7782-50-5 |
|
x |
|
|
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
458 |
síran xxxxxx |
XX |
231-984-1 |
7783-20-2 |
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
473 |
xxxxxxxxxx x xxxxxxxxxxx |
XX |
232-319-8 |
8003-34-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
491 |
xxxx chloričitý |
XX |
233-162-8 |
10049-04-4 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
494 |
2,2-dibrom-2-kyanacetamid (XXXXX) |
XX |
233-539-7 |
10222-01-2 |
|
x |
|
x |
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
501 |
xxxxxxxxxxx |
XX |
234-232-0 |
10605-21-7 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
|
515 |
xxxxxx amonný |
SE |
235-183-8 |
12124-97-9 |
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
522 |
zink-1-oxo-1λ5-pyridin-2-thiolát |
SE |
236-671-3 |
13463-41-7 |
|
x |
|
|
|
x |
x |
|
x |
x |
|
|
|
|
|
|
x |
|
|
524 |
dodecylguanidin-monohydrochlorid |
XX |
237-030-0 |
13590-97-1 |
|
|
|
|
|
x |
|
|
|
|
x |
|
|
|
|
|
|
|
|
526 |
xxxxxx-xxxxxxx-2-xxxx |
XX |
237-243-9 |
13707-65-8 |
|
|
|
|
|
x |
|
|
x |
x |
|
|
x |
|
|
|
|
|
|
529 |
xxxxxxxxxxxxxxx |
XX |
237-601-4 |
13863-41-7 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
531 |
(benzyloxy)methanol |
XX |
238-588-8 |
14548-60-8 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
534 |
xxx(1-xxxxxxxxxxxxxx-2(1X)-xxxxxxxx-X,X)xxxxxxx xxxxxxx (xxxxxxxxx xxxx) |
XX |
238-984-0 |
14915-37-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
541 |
natrium-4-chlor-3-methylfenolát |
XX |
239-825-8 |
15733-22-9 |
x |
x |
x |
|
|
x |
|
|
x |
|
|
|
x |
|
|
|
|
|
|
550 |
5,5′-xxx(4-xxxxxxxxxx)-1,1′-(xxxxx-1,6-xxxx)xxx(xxxxxxxx)-xxx(x-xxxxxxxx) (CHDG) |
XX |
242-354-0 |
18472-51-0 |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
554 |
4-[(xxxxxxxxxxx)xxxxxxxx]-1-xxxxxxxxxxxx |
UK |
243-468-3 |
20018-09-1 |
|
|
|
|
|
x |
x |
|
x |
x |
|
|
|
|
|
|
|
|
|
559 |
[(benzothiazol-2-yl)sulfanyl]methyl-thiokyanát (XXXXX) |
X |
244-445-0 |
21564-17-0 |
|
|
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
|
562 |
[2-xxxxxx-4-xxx-3-(xxxx-2-xx-1-xx)xxxxxxxxx-2-xx-1-xx]-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (prallethrin) |
XX |
245-387-9 |
23031-36-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
563 |
xxxxxx-(X,X)-xxxx-2,4-xxxxxxx (xxxxxx xxxxxxxx) |
XX |
246-376-1 |
24634-61-5 |
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
566 |
α, α′,α′′-xxxxxxxxxxxxxxxxxx-1,3,5-xxxxxxx-1,3,5-xxxxxxxxxx (HPT) |
XX |
246-764-0 |
25254-50-6 |
|
x |
|
|
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
571 |
2-xxxxxxxxxxxxxxxxxxxxxxxxx-3-xx (XXX) |
XX |
247-761-7 |
26530-20-1 |
|
|
|
|
|
x |
x |
|
x |
x |
x |
|
x |
|
|
|
|
|
|
577 |
xxxxxxxx(xxxxxxxxx)[3-(xxxxxxxxxxxxxxx)xxxxxx]xxxxxxx-xxxxxxx |
XX |
248-595-8 |
27668-52-6 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
578 |
X2-xxxx-xxxxx-X4-xxxxxxxxxxx-6-(xxxxxxxxxxxxxx)-1,3,5-xxxxxxx-2,4-xxxxxx (xxxxxxxx) |
XX |
248-872-3 |
28159-98-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
588 |
xxxxxxxxx-5,5-xxxxxxxxxxxxxxxxxxxx-2,4-xxxx (XXXXX/xxxxxxxxxxxxxxxxxxxxxxxxxx) |
NL |
251-171-5 |
32718-18-6 |
|
x |
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
590 |
3-(4-xxxxxxxxxxxxxx)-1,1-xxxxxxxxxxxxxxxx/xxxxxxxxxxx |
XX |
251-835-4 |
34123-59-6 |
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
|
|
|
597 |
1-[2-(xxxxxxxx)-2-(2,4-xxxxxxxxxxxx)xxxxx]xxxxxxxx (xxxxxxxx) |
XX |
252-615-0 |
35554-44-0 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
599 |
X-[(6-xxxxx-2-xxxxxxxxxx[4,5-x]xxxxxxx-3(2X)-xx)xxxxxx]-X,X-xxxxxxxx-xxxxxxxxxxxxx (xxxxxxxxxxx) |
XX |
252-626-0 |
35575-96-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
600 |
2-xxxx-2-(xxxxxxxxxx)xxxxxxxxxxxxxx (XXXXX) |
XX |
252-681-0 |
35691-65-7 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
961 |
xxxx vápenato-hořečnatý/dolomitické xxxxx |
XX |
253-425-0 |
37247-91-9 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
962 |
xxxxxxxx vápenato-hořečnatý/hydratované dolomitické xxxxx |
XX |
254-454-1 |
39445-23-3 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
606 |
[(3-xxxxxxxxxxx)xxxxxxxxxx]-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (xxxxxxxxxxx) |
EL |
254-484-5 |
39515-40-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
608 |
dimethyl(tetradecyl)[3-(trimethoxysilyl)propyl]amonium-chlorid |
XX |
255-451-8 |
41591-87-1 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
609 |
xxx- a xxxxx-x-xxxxxxx-3,8-xxxx (xxxx) (xxxxxxxxxx) |
XX |
255-953-7 |
42822-86-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
614 |
(XX)-α-xxxxx-3-xxxxxxxxxxxx-(1XX)-xxx,xxxxx-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
257-842-9 |
52315-07-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
615 |
3-xxxxxxxxxxxx(1XX,3XX;1XX,3XX)-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (xxxxxxxxxx) |
IE |
258-067-9 |
52645-53-1 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
618 |
[1-ethynyl-2-methylpent-2-en-1-yl]-2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyklopropan-1-karboxylát (xxxxxxxxxx) |
BE |
259-154-4 |
54406-48-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
619 |
3-jodprop-2-yn-1-yl-N-butylkarbamát (XXXX) |
XX |
259-627-5 |
55406-53-6 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
620 |
xxxxxxxx(xxxxxxxxxxxxx)xxxxxxxxx-xxxxxx (2:1) (XXXX) |
XX |
259-709-0 |
55566-30-8 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
628 |
(±)-1-{[2-(2,4-xxxxxxxxxxxx)-4-xxxxxx- 1,3-xxxxxxxx-2-xx]xxxxxx}-1X-1,2,4-xxxxxxx (propikonazol) |
XX |
262-104-4 |
60207-90-1 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
635 |
xxxxxxxxxxxxxxxxxxxxxxxxxxxxx kokosového xxxxx (ATMAC/TMAC) |
XX |
263-038-9 |
61789-18-2 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
648 |
4,5-dichlor-2-oktylisothiazol-3(2H)-on (4,5-xxxxxxx- 2-xxxxx-2X-xxxxxxxxxx-3-xx (XXXXX)) |
N |
264-843-8 |
64359-81-5 |
|
|
|
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
|
649 |
1-(2-xxxxxxxxxxx)-3-[(xxxxxxxxxxxxxxx)xxxxx]xxxxxxxx (xxxxxxxxxxx) |
IT |
264-980-3 |
64628-44-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
656 |
bis(5-methyloxazolidin-3-yl)methan (xxxxxxxxxx/XXX) |
XX |
266-235-8 |
66204-44-2 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
657 |
6-(xxxxxxxxxxxxxxxx)-1,3,5-xxxxxxx-2,4-xxxxxx (cyromazin) |
XX |
266-257-8 |
66215-27-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
666 |
[(3-xxxxxx-4-xxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx (xxxxxxxxxx) |
XX |
269-855-7 |
68359-37-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
667 |
xxxxx(X12-18)xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXXX (C12-18)) |
IT |
269-919-4 |
68391-01-5 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
671 |
xxxxx(X12-16)xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (ADBAC/BKC (X12-X16)) |
XX |
270-325-2 |
68424-85-1 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
673 |
xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx (DDAC) (X8-10) |
XX |
270-331-5 |
68424-95-3 |
x |
x |
x |
x |
|
x |
|
|
|
x |
x |
x |
|
|
|
|
|
|
|
690 |
xxxxx(X12-X18)xxxxxx(xxxxxxxx)xxxxxxxx xxxx 1,1-xxxxx-1λ-1,2-xxxxxxxxxxxxxxx-3(2X)-xxx (XXXXX) |
XX |
273-545-7 |
68989-01-5 |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
691 |
natrium-N-(hydroxymethyl)glycinát |
XX |
274-357-8 |
70161-44-3 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
692 |
xxxxx(X10-X16)xxxxxxxxxxxxxxxxx |
PT |
274-687-2 |
70592-80-2 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
693 |
bis(peroxosíran)-bis(síran) xxxxxxxxxxxxx |
XX |
274-778-7 |
70693-62-8 |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
701 |
xxxxxxxxx-xxxxxxxxxxxxxxxx xxxxxxxxxx (MMPP) |
PL |
279-013-0 |
84665-66-7 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1015 |
margosa, Xxxxxxxxxxx indica, xxxxxxx |
XX |
283-644-7 |
84696-25-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
724 |
xxxxx(X12-X14)xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXXX (X12-X14)) |
XX |
287-089-1 |
85409-22-9 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
725 |
alkyl(C12-C14)ethylbenzylammoniumchlorid (ADEBAC (X12-X14)) |
XX |
287-090-7 |
85409-23-0 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
731 |
xxxxxxxxx xxxxxxxxxxxx, Xxxxxxxxxxxxx xxxxxxxxxxxxxxxx, výtažek |
XX |
289-699-3 |
89997-63-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
744 |
xxxxxxxxx zvrhlá, Xxxxxxxxx xxxxxxx, výtažek/levandulový xxxx |
XX |
294-470-6 |
91722-69-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
776 |
1-[3,5-xxxxxxx-4-(1,1,2,2-xxxxxxxxxxxxxxxx)xxxxx]-3-(2,6-xxxxxxxxxxxxxx)xxxxxxxx (hexaflumuron) |
XX |
401-400-1 |
86479-06-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
779 |
xxxxxxx produkty xxxxxxxxx xxxxxxxx x X-xxxxx(X12-X14)xxxxxx-1,2-xxxxxxx (glukoprotamin) |
XX |
403-950-8 |
164907-72-6 |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
785 |
6-xxxxxxxxxxxxxxxxxxxxxxx kyselina (XXX) |
XX |
410-850-8 |
128275-31-0 |
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
791 |
2-xxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx (XXXX) |
XX |
420-590-7 |
4299-07-4 |
|
|
|
|
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
792 |
komplex xxxxxxxxxxxxxxxxxxx (XXXX) |
XX |
420-970-2 |
92047-76-2 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
811 |
xxxxxxxxxxxxxxxxxxx stříbrno-sodno-zirkoničitý |
SE |
422-570-3 |
265647-11-8 |
x |
x |
|
x |
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
794 |
sek-butyl-2,2-(2-hydroxyethyl)piperidin-1-karboxylát (ikaridin) |
DK |
423-210-8 |
119515-38-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
797 |
1-((X)-3-xxxxxxxxxx)-3,5,7-xxxxxx-1-xxxxxxxxxxxxxxxxxxxxxx (xxx-XXXX) |
XX |
426-020-3 |
51229-78-8 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
800 |
{[2,5-xxxxx-3-(xxxx-2-xx-1-xx)xxxxxxxxxxxx-1-xx]xxxxxx}-2,2-xxxxxxxx-3- (2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx- 1-karboxylát (xxxx stereoisomerů) (xxxxxxxxxxx) |
UK |
428-790-6 |
72963-72-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
790 |
5-xxxxx-2-(4-xxxxxxxxxxx)xxxxx (XXXX) |
XX |
429-290-0 |
3380-30-1 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
807 |
(X)-1-[(2-xxxxxxxxxxxx-5-xx)xxxxxx]-3-xxxxxx-2-xxxxxxxxxxxxx (xxxxxxxxxxxxx) |
DE |
433-460-1 |
210880-92-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
952 |
Bacillus xxxxxxxxxx 2362, xxxx XXXX-1743 |
XX |
mikroorganismus |
143447-72-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
955 |
Xxxxxxxx xxxxxxxxxxxxx xxxxx. xxxxxxxxxxx, xxxx XX3X |
XX |
mikroorganismus |
není relevantní |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
957 |
Xxxxxxxx xxxxxxxx |
XX |
xxxxxxxxxxxxxxx |
xxxx relevantní |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
928 |
5-xxxxx-2-xxxxxxxxxxxxxxxx-3(2X)-xx (Xxxxxx 247-500-7) x 2-methylisothiazol-3(2H)-on (Xxxxxx 220-239-6), směs (3:1) (xxxx XXXX/XXX) |
XX |
směs |
55965-84-9 |
|
x |
|
x |
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
939 |
aktivní xxxxx (vyráběný xxxxxx xxxxxxxx xxxxxxx x xxxxxxxxx sodného xx xxxx) |
XX |
xxxx |
xxxx xxxxxxxxxx |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
813 |
xxxxxxxxxxxxxx xxxxxxxx |
XX |
není xxxxxxxxxx |
33734-57-5 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1014 |
xxxxxxxx xxxxxx |
SE |
xxxx xxxxxxxxxx |
není xxxxxxxxxx |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
849 |
3-xxxxxxxxxxxx-(1X,3XX)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (x-xxxxxxxxx) |
XX |
xxxx xxxxxxxxxx |
188023-86-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
931 |
alkyltrimethylendiaminy, X-X12-14(xx xxxxx číslem), xxxxxxxx xxxxxx s xxxxxxxxxxxx xxxxxxxxx (Xxxxxxxx 20) |
XX |
xxxx xxxxxxxxxx |
139734-65-9 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
152 |
xxxxxxxx reakce 5,5-xxxxxxxxxxxxxxxxxx, 5-ethyl-5-methylhydantoinu x xxxxxx x chlorem (XXXXX) |
XX |
xxxx x xxxxxxxxx |
xxxx k dispozici |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
459 |
xxxxxxx xxxx xxxxx xxxxxxxxxxxx x xxxxxxxx xxxxxxxxxx |
XX |
xxxx x xxxxxxxxx |
xxxx k dispozici |
x |
x |
|
|
|
x |
x |
|
x |
x |
x |
|
|
|
|
|
|
|
|
777 |
xxxxxxx xxxxxxxx 5,5-xxxxxxxxxxxxxxxxxx, 5-xxxxx-5-xxxxxxxxxxxxxxxx x xxxxxxx (XXXXX) |
XX |
xxxx x xxxxxxxxx |
xxxx x xxxxxxxxx |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
810 |
xxxxxxxxxxxxxx xxxx x xxxxxxx xxxxxxx |
XX |
xxxx x xxxxxxxxx |
308069-39-8 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
824 |
stříbrno-zinečnatý xxxxxx |
XX |
xxxx x xxxxxxxxx |
130328-20-0 |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
1013 |
xxxxxxxx-xxxxxxx xxxxxx |
XX |
xxxx x xxxxxxxxx |
130328-19-7 |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
1017 |
xxxxxxx xxxxxxxxxxx na xxxxx xxxxxxxxxx (xxxx xxxxxxxxxxxx xx xxxxx xxxxxxxxxx agregátu x primárními částicemi xx nanoúrovni) |
XX |
xxxx x xxxxxxxxx |
xxxx x xxxxxxxxx |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
1019 |
xxxx křemičitý (jako xxxxxxxxxxxx xxxxxxx xxxxxxxx x xxxxxxxxxx) |
XX |
xxxx x xxxxxxxxx |
68909-20-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
831 |
křemelina |
FR |
přípravek xx xxxxxxx xxxxxxx |
61790-53-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
854 |
(XX)-3-xxxx-2-xxxxx-4-xxxxxxxxxxxx-2-xxxx-(1X,3X;1X,3X)-2,2-xxxxxxx-3-(2-xxxxxxxxx-1-xxxx)-xxxxxxxxxxxxxxxxxxxxx (xxxx 4 xxxxxxx 1X xxxxx, 1R: 1X xxxxx, 1X: 1X xxx, 1X: 1R xxx, 1X 4:4:1:1) (x-xxxxxxxxx) |
XX |
xxxxxxxxx xx xxxxxxx xxxxxxx |
231937-89-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
855 |
(XX)-3-xxxxx-2-xxxxxx-4-xxxxxxxxxxxx-2-xx-1-xx-(1X,3X)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (xxxx 2 xxxxxxxxxxxxx) (esbiothrin) |
XX |
přípravek na xxxxxxx xxxxxxx |
260359-57-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
848 |
X-[(6-xxxxx-3-xxxxxxx)xxxxxx]-X′-xxxx-X-xxxxxxxxxxxxxxxxxxx (acetamiprid) |
XX |
přípravek xx xxxxxxx rostlin |
160430-64-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
835 |
esfenvalerát/(S)-(3-fenoxyfenyl)kyanmethyl-(S)-2-(4-chlorfenyl)-3-methylbutanoát (xxxxxxxxxxxx) |
XX |
xxxxxxxxx xx ochranu xxxxxxx |
66230-04-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
836 |
[(3-xxxxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx (α-cypermethrin) |
BE |
xxxxxxxxx xx xxxxxxx rostlin |
67375-30-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
843 |
4-xxxx-2-(4-xxxxxxxxxx)-1-(xxxxxxxxxxxx)-5-(xxxxxxxxxxxxxx)xxxxxx-3-xxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
xxxxxxxxx xx ochranu rostlin |
122453-73-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
859 |
xxxxxxx X-xxxxxxxxxxxxxxxxx(XXXXXX 204-697-4) s (xxxxxxxxxxx)xxxxxxxx (EINECS 203-439-8)/xxxxxxxxx xxxxxxxxx xxxxxxx xxxxxx (XX Xxxxxxx) |
HU |
polymer |
25988-97-0 |
|
x |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
863 |
poly(biguanid-1,5-diylhexan-1,6-diyl) (XXXX) |
XX |
xxxxxxx |
27083-27-8/32289-58-0 |
x |
x |
x |
x |
x |
x |
|
|
x |
|
x |
|
|
|
|
|
|
|
|
868 |
poly(biguanid-1,5-diylhexan-1,6-diyl-hydrochlorid) |
XX |
polymer |
91403-50-8 |
x |
x |
x |
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
869 |
α-[2-(xxxxxxxxxxxxxxxxxxx)xxxxx]-ω-[xxxxxxxxxxx(xxxxxxxxxx)-xxxxxxxxx] (Xxxxxx 26) |
XX |
polymer |
94667-33-1 |
|
x |
|
x |
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
872 |
X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxx-xxxxx/ α, α ′-(xxxxxxxxxxxxx)xxx[ω-xxxxxxxxx(xxxxxxxxxx)]-xxx xx (xxxxxxxxxxx xxxxxx) |
XX |
xxxxxxx |
214710-34-6 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
XXXX 2
Xxxxxxxxx účinné xxxxx x xxxx přípravku xxxxxxxxxxxxx xx dni 4. xxxxx 2014
Xxxx část xxxx xxxxxxx xxxxxxxx
|
— |
kombinace xxxxx a typu xxxxxxxxx xxxxxxx x xxxxxxx xxxx, xxxxxx xxxxxxxxxx xxxxxxxxx, |
|
— |
jakékoli xxxxxxxxx xxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxxxx x xxxxxxx x xxxxx 1, xxxxx xxxx, které xxxx uvedeny x xxxxxxx, x |
|
— |
xxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxxxxxx xx 4. xxxxx 2014, x xxxxxxxx těch, které xxxx xxxxxxxx xxxxxxxxx. |
Xxxxxxxxx xxxxx x xxxx přípravku x xxxxxxxxxxxxx xxxxxxxx xx xxxx xxxxx xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxxxx xxxxx xxxxxx 20, xxxxxxxx xxxxx xxxxx xxxxxx xxxxxxxx xx xxxxxxxx xxxxxx xx xxxxxx xxxxxx xxxxxxxx v platnost xxxxx xx. 14 xxxx. 3 xxxx xxxxx xx xxxxxx xxxxxxxx xxxxxxxxx xxxxx xx. 17 xxxx. 4 nebo 5.
|
Xxxxx položky |
Xxxxx látky |
Xxxxxxx xxxx zpravodaj |
Xxxxx XX |
Xxxxx XXX |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
17 |
18 |
19 |
21 |
22 |
|
1021 |
1,3-xxxxxxx-5,5-xxxxxxxxxxxxxxxxx (xxxx definovaný xxxxx položky 152) |
XX |
204-258-7 |
118-52-5 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
166 |
benzyl(hexadecyl)dimethylamonium-chlorid (xxx xxxxxxx 948) |
|
204-526-3 |
122-18-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
167 |
benzyl(dimethyl)oktadecylamonium-chlorid (xxx položka 948) |
|
204-527-9 |
122-19-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
213 |
benzyl(dodecyl)dimethylamonium-chlorid (xxx položka 948) |
|
205-351-5 |
139-07-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
214 |
xxxxxx(xxxxxxxx)xxxxxxxxxxxxxxxxx-xxxxxxx (xxx položka 948) |
|
205-352-0 |
139-08-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
227 |
2-(xxxxxxx-4-xx)xxxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
205-725-8 |
148-79-8 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
331 |
xxxxxxxxxxxxxxxxxxxxxx-xxxxxx (xxx položka 949) |
|
219-234-1 |
2390-68-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
384 |
xxxxxxxx(xxxxxxx)xxxxxxx-xxxxxxx (xxx položka 949) |
|
226-901-0 |
5538-94-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
399 |
xxxxxx(xxxxxxx)xxxxxxxxxxxxxxx-xxxxxx (viz xxxxxxx 948) |
|
230-698-4 |
7281-04-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
401 |
xxxxxxx |
XX |
231-131-3 |
7440-22-4 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
418 |
xxxx xxxxxxxxx xxxxxxx |
FR |
231-545-4 |
7631-86-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
449 |
xxxxx xxxxxxx |
XX |
231-847-6 |
7758-98-7 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1016 |
xxxxxxx xxxxxxxx |
SE |
232-033-3 |
7783-90-6 |
x |
x |
|
|
|
x |
x |
|
x |
x |
x |
|
|
|
|
|
|
|
|
554 |
4-[(dijodmethyl)sulfonyl]-1-methylbenzen |
XX |
243-468-3 |
20018-09-1 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
587 |
xxxxx(xxxxxxxx)xxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 949) |
|
251-035-5 |
32426-11-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
601 |
xxxxxxxxxxxxxx(xxxxxxx-9-xx-1-xx)xxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
253-363-4 |
37139-99-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
615 |
3-xxxxxxxxxxxx(1XX,3XX;1XX,3XX)-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (xxxxxxxxxx) |
XX |
258-067-9 |
52645-53-1 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
637 |
xxxxx(xxxxxx)xxxxxxxxxxxxxxx-xxxxxxxx (xxxxx xxxxxxx xx xxxxxxxx kyselin xxxxxxxxxx xxxxx) (xxx položka 948) |
|
263-080-8 |
61789-71-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
638 |
xxxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxxxx odvozen xx mastných kyselin xxxxxxxxxx xxxxx) (xxx xxxxxxx 949) |
|
263-087-6 |
61789-77-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
639 |
xxxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (alkyl xxxxxxx xx xxxxxxxxxxxxxxx xxxxxxxx xxxxxxx xxxx) (xxx položka 949) |
|
263-090-2 |
61789-80-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
647 |
xxxxx(X8-X18)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxx položka 948) |
|
264-151-6 |
63449-41-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
668 |
xxxxxxx(X6-X12)xxxxxxxxxxxxxxx-xxxxxxxx (xxx položka 949) |
|
269-925-7 |
68391-06-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
670 |
xxxxx(X8-X16)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxx položka 948) |
|
270-324-7 |
68424-84-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
689 |
xxxxx(X10-X16)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxx xxxxxxx 948) |
|
273-544-1 |
68989-00-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
692 |
xxxxx(X10-X16)xxxxxxxxxxxxxxxxx |
PT |
274-687-2 |
70592-80-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
697 |
xxxxxxx(X8-X18)xxxxxxxxxxxxxx-xxxxxxxx (xxx xxxxxxx 949) |
|
277-453-8 |
73398-64-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1000 |
xxxxxxxxxx-xxx(xxxxxxxxxxxxxxxxx)xxxxxxxx xxxxxxxxxx |
XX |
279-013-0 |
14915-85-4 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
998 |
xxxxxxx xxxxxxx xxxx xxx x xxxxx xxxxxxxx Xxxxxxxxxxx indica xxxxxxxxxxx vodou a xxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx |
XX |
283-644-7 |
84696-25-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
741 |
xxxxx(X8-X18)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxx (viz xxxxxxx 948) |
|
293-522-5 |
91080-29-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1020 |
1,3-xxxxxxx-5-xxxxx-5-xxxxxxxxxxxxxxxxxx-2,4-xxxx (xxxx definovaný xxxxx xxxxxxx 777) |
NL |
401-570-7 |
89415-87-2 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
778 |
1-(4-chlorfenyl)-4,4-dimethyl-3-[(1H-1,2,4-triazol-1-yl)methyl]pentan-3-ol (xxxxxxxxxxx) |
XX |
403-640-2 |
107534-96-3 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
805 |
xxxxxxx produkt dimethyl-adipátu, xxxxxxxx-xxxxxxxxx x xxxxxxxx-xxxxxxxxx x xxxxxxxxx xxxxxx (xxxxxxxx) |
XX |
432-790-1 |
xxxx xxxxxxxxxx |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
923 |
xxxxx(xxxxxx)xxxxxxxxxxxxxxx-xxxxxxx/xxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
xxxx |
8001-54-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
949 |
(dialkyl)dimethylamonium-chloridy, -xxxxxxx xxxx -xxxxxx-xxxxxxx) (alkyly (X6-X18) xxxxxxxx x xxxxxxxxxx, odvozené xx xxxxxxxx xxxxxxx loje, xxxxxxxxxx oleje a xxxxxxxx xxxxx) (XXXX) |
IT |
xxxx xxxxx xxxxxxxxx v xxxxxxx EINECS |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
950 |
alkyltrimethylamonium-chloridy, -xxxxxxx xxxx -xxxxxx-xxxxxxx) (xxxxxx (X8-X18) xxxxxxxx x xxxxxxxxxx, xxxxxxxx xx mastných kyselin xxxx, xxxxxxxxxx xxxxx x xxxxxxxx oleje) (XXXX) |
XX |
xxxx látek uvedených x xxxxxxx XXXXXX |
xxxx xxxxxxxxxx |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
948 |
xxxxxx(xxxxx)xxxxxxxxxxxxxxx-xxxxxxxx, -bromidy xxxx -xxxxxxxxx) (xxxxxx (C8-C22) xxxxxxxx x xxxxxxxxxx, xxxxxxxx od xxxxxxxx xxxxxxx loje, xxxxxxxxxx xxxxx x xxxxxxxx oleje) (XXX) |
XX |
xxxx xxxxx xxxxxxxxx x xxxxxxx XXXXXX |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
849 |
3-xxxxxxxxxxxx-(1X,3XX)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (x-xxxxxxxxx) |
XX |
xxxx xxxxxxxxxx |
188023-86-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
1001 |
alkyl(C12-C16)benzyl(dimethyl)amonium-chloridy (xxxx než xxxxx xxxxxxxxx xxx xxxxxxx 671) |
XX |
xxxx xxxxxxxxxx |
xxxx relevantní |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
x |
|
1002 |
xxxxx(X12-X18)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx(xxxx xxx xxxxx xxxxxxxxx xxx položku 667) |
XX |
xxxx xxxxxxxxxx |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
1003 |
xxxxx(X12-X18)(xxxxxxxxxxx)xxxxxxxxxxxxxxx- xxxxxxxx (xxxx xxx látka xxxxxxxxx pod xxxxxxx 725) |
XX |
xxxx xxxxxxxxxx |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
1005 |
xxxxx(X12-X14)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxxx než xxxxx xxxxxxxxx pod položku 724) |
XX |
xxxx xxxxxxxxxx |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
1006 |
fosforečnanové xxxx xxxxxxxxxx stříbro, xxxxx, xxxxxx x xxx |
XX |
xxxx relevantní |
398477-47-9 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
1009 |
dialkyl(C8-C10)dimetylamonium-chloridy (jiné xxx xxxxx xxxxxxxxx xxx položku 673) |
IT |
xxxx xxxxxxxxxx |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
x |
x |
|
|
|
x |
x |
x |
|
|
|
|
|
|
|
1011 |
alkyl(trimethyl)amonium-chloridy (alkyl xxxxxxx od xxxxxxxx xxxxxxx xxxxxxxxxx oleje) (xxxx než látka xxxxxxxxx pod xxxxxxx 635) |
XX |
xxxx xxxxxxxxxx |
xxxx xxxxxxxxxx |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
1012 |
hlinitokřemičitan xxxxx, xxxxxxxx a xxxxxxxxx komplex/stříbrno-zinečnatý zeolit |
XX |
xxxx xxxxxxxxxx |
130328-20-0 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
598 |
(±)-1-(β-xxxxxxxx-2,4-xxxxxxxxxxxxxxxxx)xxxxxxxx (xxxxxxxx technický) |
DE |
přípravek xx ochranu xxxxxxx |
73790-28-0 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
XXXXXXX XXX
Xxxxx
|
Xxxx xxxxxxxxx |
Xxxxx pro xxxxxxxxxx xxxxxxxxx xxxxxx xxxxx xx. 6 xxxx. 3 xxxx. x) |
Xxxxx pro zahájení xxxxxxxx xxxxxxxxxx xxxxx xx. 7 odst. 2 xxxx. x) |
|
8, 14, 16, 18, 19 x 21 |
31.12.2015 |
31.3.2016 |
|
3, 4 x 5 |
31.12.2016 |
31.3.2017 |
|
1 x 2 |
31.12.2018 |
31.3.2019 |
|
6 x 13 |
31.12.2019 |
31.3.2020 |
|
7, 9 a 10 |
31.12.2020 |
31.3.2021 |
|
11, 12, 15, 17, 20 x 22 |
31.12.2022 |
31.9.2023 |